Southeast Asia Launches First-Ever Regional Consortium to Decode the "Asian Brain" and Combat Dementia Crisis

Spread the Message

Read Time:5 Minute, 0 Second

Dateline: SINGAPORE, December 1, 2025

In a landmark move to address one of the region’s most pressing public health challenges, Nanyang Technological University, Singapore (NTU Singapore) has spearheaded the formation of the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research Plus (SEACURE+). Officially launched on November 28, 2025, this first-of-its-kind initiative unites clinicians and researchers from eight nations to develop dementia treatments tailored specifically to the unique biological and cultural traits of the Asian population.

The consortium, which expands upon a working group formed in 2023, now includes member countries Singapore, Malaysia, Thailand, Vietnam, the Philippines, Indonesia, Brunei, and Myanmar, with China and India joining as honorary members.

The “Asian Phenotype”: Why Region-Specific Research Matters

For decades, dementia research has been dominated by data from Western populations, predominantly white cohorts in North America and Europe. However, emerging evidence suggests that dementia manifests differently in Asian populations, rendering some Western-centric diagnostic criteria and treatment protocols less effective.

SEACURE+ aims to bridge this gap by pooling data from the region’s 700 million people. Early findings from the Biomarkers and Cognition Study, Singapore (BIOCIS)—a cornerstone project of the new consortium—have already illuminated critical biological differences:

Vascular Drivers Over Genetics: While the APOE-E4 gene is a primary risk factor for Alzheimer’s in Western populations, the BIOCIS study found it accounted for only 20% of Mild Cognitive Impairment (MCI) cases among Asian participants.
The “Leaky” Barrier: Researchers identified dysfunction in the blood-brain barrier—specifically “leakiness,” where the barrier fails to regulate substance movement—as a major mechanism driving cognitive decline in Asians.
Vascular Health: A striking 40% of participants with MCI showed signs of narrowing blood vessels, pointing to a stronger link between vascular health (hypertension, diabetes) and dementia in Asia than previously understood.

“The pathways driving cognitive decline in Asian populations differ significantly from those observed in Western populations,” said Associate Professor Nagaendran Kandiah, Director of the Dementia Research Centre at LKCMedicine and Chair of SEACURE+. “This reinforces the critical need for region-specific research, diagnostics, and interventions.”

A Ticking Time Bomb

The launch of SEACURE+ comes at a critical juncture. Southeast Asia is aging rapidly, with dementia prevalence projected to skyrocket. According to World Health Organization (WHO) data, the number of people living with dementia in the Southeast Asia Region is expected to nearly double from 5.5 million in 2015 to over 9.6 million by 2030.

“Southeast Asians have many commonalities in their culture, beliefs, and lifestyle risk factors,” noted Professor Tan Maw Pin, a SEACURE+ member from Universiti Malaya, Malaysia. “With our countries being among the fastest-ageing nations globally, early detection is crucial if we are in any way able to address this unprecedented increase in cases.”

Closing the Diagnosis Gap

A key focus for the consortium is “Mild Cognitive Impairment” (MCI), often considered a pre-dementia stage. SEACURE+ member clinics have reported a rising trend in patients presenting with MCI, offering a narrow but vital window for intervention to slow disease progression.

However, cultural stigma and low health literacy remain significant barriers. “Since the signs and symptoms of early stages of MCI are usually not obvious… it is likely there are more patients who are not getting the diagnosis and management they need,” Assoc Prof Kandiah explained.

To combat this, the consortium plans to:

Validate Cognitive Tests: Adapt screening tools to account for the region’s linguistic and cultural diversity.
Deploy Digital Diagnostics: Roll out digital cognitive evaluation tools developed at NTU’s Dementia Research Centre to member countries.
Harmonize Protocols: Create a unified standard for blood-based biomarker testing and care management across the region.

Expert Perspectives

Independent experts have long called for such a shift in global dementia research. Professor Charles Marshall, a Clinical Neurologist at Queen Mary University of London who has studied dementia presentation in diverse ethnic groups, emphasizes that a “one-size-fits-all” approach is insufficient.

“We tend to focus mainly on memory problems as the reason for assessing someone for dementia,” Professor Marshall noted in a 2025 study on diverse populations. “But… for cultural reasons, people [from diverse backgrounds] may be more or less likely to report memory difficulty.”

His research supports the SEACURE+ rationale, suggesting that distinct presentations—such as physical symptoms like dizziness or sleep disturbances—may be more common early indicators in Asian populations than the classic ‘memory loss’ model favored in the West.

Implications for Public Health

For the average person in Southeast Asia, the work of SEACURE+ promises a shift toward precision medicine. Instead of generic advice, future treatments could focus heavily on vascular health—managing blood pressure and cholesterol—as a primary defense against dementia.

Furthermore, the inclusion of China and India as honorary members allows for massive comparative studies. This will help disentangle how much of dementia risk is genetic (nature) versus environmental (nurture), such as diet, pollution, and lifestyle, which vary drastically across the continent.

Challenges Ahead

Despite the optimism, the consortium faces hurdles. Healthcare infrastructure varies wildly across the region, from the advanced medical hubs of Singapore to resource-limited rural areas in Myanmar and Indonesia. Implementing sophisticated blood-based biomarker tests or digital diagnostics in remote areas will require significant investment and policy support.

Moreover, changing the cultural narrative—that memory loss is not a normal part of aging but a treatable medical condition—will require sustained public education campaigns alongside clinical advancements.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.